您的购物车当前为空
别名 SQ 22536, 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine
SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) 是一种腺苷酸环化酶抑制剂。


为众多的药物研发团队赋能,
让新药发现更简单!
SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) 是一种腺苷酸环化酶抑制剂。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 185 | In Stock | |
| 5 mg | ¥ 398 | In Stock | |
| 10 mg | ¥ 622 | In Stock | |
| 25 mg | ¥ 1,370 | In Stock | |
| 50 mg | ¥ 2,370 | In Stock | |
| 100 mg | ¥ 3,790 | In Stock | |
| 200 mg | ¥ 4,780 | 待询 | |
| 1 mL x 10 mM (in DMSO) | ¥ 452 | In Stock |
SQ22536 相关产品
| 产品描述 | SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) , the adenosine analogue 9-(Tetrahydro-2-furyl)adenine, inhibited adenylate cyclase activity of crude membrane preparations from catfish (Ictalurus melas) and rat isolated hepatocytes in a non-competitive manner. |
| 体外活性 | SQ22536 (250 μMol/L) 减弱了腺苷对ADP诱导的血小板聚集的抑制效应,将其从8±5%降至57±5%(p<0.001)。SQ22536同样减弱了腺苷使血小板内cAMP水平上升的效应,从29±2 pmol/108血小板降至9±1 pmol/108血小板(p<0.05)。它对肌苷(1至4 mmol/L)的血小板抗聚集活性及ADP诱导的血小板聚集[4]没有影响。 |
| 体内活性 | SQ22536消除了利拉鲁肽对KK/Ta-Akita小鼠肾脏保护作用。在与SQ22536联合处理的KK/Ta-Akita小鼠中,利拉鲁肽改善肾小球组织病理损伤的作用被消除。经SQ22536处理后,肾脏cAMP水平不增加。总之,SQ22536这一腺苷酸环化酶抑制剂抑制了利拉鲁肽治疗肾病的有益作用[5]。 |
| 细胞实验 | HMC-1 cells and hCBMCs are plated in 48-well plates and serum-starved overnight. The next day, cells are preincubated with SQ22536 at the indicated concentrations for 30 min before stimulation with CRH (100 nM for HMC-1 or 1 μM for hCBMC) for 3 min in the presence or absence of SQ22536 in serum-free culture media. Cell lysates are then prepared and assayed for protein kinase A activity using ELISA.(Only for Reference) |
| 别名 | SQ 22536, 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine |
| 分子量 | 205.22 |
| 分子式 | C9H11N5O |
| CAS No. | 17318-31-9 |
| Smiles | Nc1ncnc2n(cnc12)C1CCCO1 |
| 密度 | 1.7 g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 10.3 mg/mL (50.19 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (9.75 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容